CROI 2013: Sofosbuvir + Ledipasvir + Ribavirin Combo for HCV Produces 100% Sustained Response
- Details
- Category: Experimental HCV Drugs
- Published on Monday, 04 March 2013 00:00
- Written by Liz Highleyman
An interferon-free regimen of the direct-acting hepatitis C drugs sofosbuvir (formerly GS-7997), ledipasvir (formerly GS-5885), and ribavirin produced a 12-week post-treatment sustained virological response (SVR12) rate of 100% for both treatment-naive patients and prior non-responders with HCV genotype 1, according to data presented today at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) in Atlanta.
CROI 2013: Case Report of a "Functional" HIV Cure in a Child
- Details
- Category: Search for a Cure
- Published on Sunday, 03 March 2013 00:00
- Written by Keith Alcorn
Researchers in the U.S. say that they have identified a case of a "functional" HIV cure in a child infected with HIV who began antiretroviral treatment within days of birth. The child has now been off treatment for over a year, and although HIV DNA has been detected at very low levels in the child’s cells, the virus is not reproducing.
CROI 2013: Retrovirus Conference Starts Sunday in Atlanta
- Details
- Category: HIV Treatment
- Published on Thursday, 28 February 2013 00:00
- Written by Liz Highleyman
The 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) kicks off Sunday, March 3, at the Georgia World Congress Center in Atlanta. HIVandHepatitis.com will be on site next week to bring you breaking news coverage on HIV and hepatitis C.
Look for reports from the HIVandHepatitis.com team and our content partners at NAM/Aidsmap.com starting Monday. Sign up for our email newsletter to get the latest headlines and follow us on Twitter @HIVandHepatitis.
Web Design and Development by